CD33-TTC

N/A

Report date: 2025/11/04 16:07:40

Base Information

Drug NameCD33-TTC

Drug Alias NameCD33-TTC

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Nuclides > Thorium > 227Th +[4]

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitors

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBayer As

China Registration ClassN/A

Develop Information

Active CompaniesBayer As

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A